Paper Review Records
全部论文审稿周期
30 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
62
天
An In Silico–In Vitro Framework for Model‐Informed Precision Dosing in Oncology: Proof‐of‐Principle for Doxorubicin in Patient‐Derived Sarcoma Spheroids
作者
Hannah K. Dorn; Micaela Freitas; Severin Manser; Marko Weidmann; Ina Oehme; Heike Peterziel; Olaf Witt; Jens M. Kelm; Lars Kuepfer展开收起
作者单位
1. Institute for Systems Medicine With Focus on Organ Interaction University Hospital RWTH Aachen University Aachen Germany; 2. PreComb Therapeutics AG Hombrechtikon Switzerland; 3. Hopp Children's Cancer Center Heidelberg (KiTZ) Heidelberg Germany; 4. Clinical Cooperation Unit Pediatric Oncology (B310) German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK) Heidelberg Germany; 5. National Center for Tumor Diseases Heidelberg Heidelberg Germany; 6. Department of Pediatric Oncology, Hematology, Immunology and Pulmonology Heidelberg University Hospital Heidelberg Germany展开收起
88
天
Nine‐Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data
作者
Romane Le Goff; Amandine Gouverneur; Cédric Collin; Pascaline Rabiega; Mathieu Molimard展开收起
作者单位
1. Real World Solutions IQVIA Paris France; 2. Department of Medical Pharmacology Bordeaux University Bordeaux France展开收起
141
天
The Relationship Between Pre‐Operative Ipilimumab and Nivolumab Pharmacokinetics and Treatment Outcome in Locoregionally Advanced Urothelial Cancer
作者
Sybrand W. J. Zielhuis; Karen A. M. de Jong; Hinke Huisman‐Siebinga; Lisa T. van der Heijden; Bart A. W. Jacobs; Jos H. Beijnen; Hilde Rosing; Chantal F. Stockem; Jeroen van Dorp; Michiel S. van der Heijden; Alwin D. R. Huitema展开收起
作者单位
1. Department of Pharmacy & Pharmacology The Netherlands Cancer Institute Amsterdam the Netherlands; 2. Department of Medical Oncology The Netherlands Cancer Institute Amsterdam the Netherlands; 3. Department of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam the Netherlands; 4. Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University Utrecht the Netherlands; 5. Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands展开收起
104
天
Application of Mechanistic Modeling to Support Dose‐Relevant Decision Making for CAR ‐T Cell Therapy in Oncology: A Systematic Scoping Review
作者
Dolapo Odujinrin; Graham McClelland展开收起
作者单位
1. Centre for Pharmaceutical Medicine Research, School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London London UK展开收起
76
天
132
天
Landscape Analysis of Digital Health Technology Use for Remote Data Acquisition in CDER ‐Regulated Submissions, 2023–2025
作者
Ayoub Suliman; Norah Xiao; Leonard Sacks; Elizabeth Kunkoski; Ryan Robinson; Dianne Paraoan; Hussein Ezzeldin; Anindita Saha; Qi Liu; Hao Zhu; Yutao Gong; Hanrui Zhang; Ruihao Huang; Jeffrey Siegel; Jonas Santiago; Elizabeth Hart展开收起
作者单位
1. Office of Medical Policy, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA; 2. Office of Translational Sciences, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA; 3. Office of Drug Evaluation Sciences, Office of New Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA展开收起
FAQ
CTS-Clinical and Translational Science审稿要多久?
截至2026-11-17,CrushSCI 收录了 CTS-Clinical and Translational Science 的 30 篇完整审稿记录。最快一篇从收稿到录用用了 31 天(Posaconazole Target Attainment in Critically Ill Children: A 15‐Year Single‐Center Retrospective Analysis,2026-07-24 收稿,2026-08-24 录用),最慢一篇用了 255 天;平均 126.0 天,中位数 123 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
